Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orphazyme A/S
Leo CEO Bourdon Plots Return To Profit This Year
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.
End of The Line Looms For Nordic Nanovector
It does not look like the Norwegian biotech can recover from the discontinuation of its lead candidate, the lymphoma drug Betalutin, and the ‘for sale’ signs are likely to be erected soon as a strategic review gets underway.
RhoVac Seeks Path Forward After Phase IIb Prostate Cancer Disappointment
Despite a seemingly sound mechanism and promising early data, the Swedish firm’s sole clinical asset has flunked a mid-stage prostate cancer trial, prompting a search for responsive subgroups.
Finance Watch: Biotech Stocks Stabilize At The End Of A Rocky Week
Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.
- Large Molecule
- Other Names / Subsidiaries
- Orphazyme US, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.